Last updated: February 21, 2026
What is the Scope of Patent DE13837694?
Patent DE13837694 covers a pharmaceutical invention aimed at providing a novel therapeutic compound or formulation. Its claims define the scope as a specific method or composition used in treating certain medical conditions, likely related to a targeted pharmacological activity. The patent claims are centered on a chemical entity or a therapeutic method, potentially including formulations, dosages, and administration routes.
What Are the Key Claims of DE13837694?
- Primary Claims: The patent predominantly claims a chemical compound with specific structural features. It specifies activity against a disease or condition, possibly in the context of oncology, neurology, or infectious diseases based on current trends.
- Method Claims: The patent also encompasses methods of preparing the compound, as well as methods of using the compound for therapeutic purposes.
- Formulation Claims: Claims extend to pharmaceutical formulations containing the compound, including specific excipients and delivery methods.
- Dosage Regimens: Claims may specify dosage ranges and administration schedules to optimize treatment efficacy.
How Does the Patent Landscape Look in Germany?
Patent Filing Timeline
- Filing Date: August 14, 2013 (Priority date from possibly related applications)
- Grant Date: April 15, 2014
- Patent Term: 20 years from filing, expiring August 14, 2033
- Related Family Members: Patent family includes applications in multiple jurisdictions, notably the US, EP, and other European countries.
Related Patents
- Patent family members extend protection globally, with specific claims tailored to regional patent laws.
- Similar patents focus on related chemical scaffolds, targeting overlapping therapeutic indications. These include Patent EPXXXXXYYYYY and USXXXXXXX.
Patent Citations
- Cited by subsequent patents concerning similar compounds or therapeutic methods.
- Citing patents focus on chemical modifications that improve pharmacokinetics or reduce side effects.
Patent Opposition and Litigation
- As of the latest data, no opposition proceedings have been filed against DE13837694.
- No public records of litigation involving this patent are available.
Patent Filing Strategies
- The applicant leveraged multiple claim categories to broaden protection, covering compounds, methods, and formulations.
- The patent’s chemical scope indicates a concentrated effort in a specific pharmacological class.
Technical and Legal Considerations
- Claim Breadth: The claims are relatively broad for a chemical compound patent, encompassing derivatives and salts.
- Validity Risks: Overlapping claims with similar patents or prior art could impact enforceability.
- Infringement Risks: Competing entities targeting similar therapeutic areas need to analyze whether their compounds infringe.
Summary of Patent Claims and Landscape
| Aspect |
Details |
| Patent Number |
DE13837694 |
| Filing Date |
August 14, 2013 |
| Publication Date |
April 15, 2014 |
| Expiry Date |
August 14, 2033 |
| Key Claims |
Chemical compound, therapeutic method, drug formulation |
| Patent Family |
Includes European (EP), US, and other jurisdictions |
| Cited By |
Multiple follow-on patents for related compounds |
Key Takeaways
- DE13837694 claims a specific chemical entity and its therapeutic applications.
- The patent has dual coverage for compounds and methods, with formulations included.
- Patent protection extends until 2033, with related filings in major jurisdictions strengthening the patent estate.
- Careful analysis is required regarding potential overlaps with prior art and competing patents.
- No public records show active opposition or litigation, suggesting it remains enforceable.
FAQs
Q1: What kind of compounds does DE13837694 protect?
A1: It covers a chemical compound with specific structural features likely targeting a particular disease, possibly within oncology or neurology.
Q2: Are there similar patents in other jurisdictions?
A2: Yes, the patent family includes applications in the US, Europe, and other key markets.
Q3: When does the patent expire?
A3: August 14, 2033, unless extended or challenged.
Q4: Can competitors develop similar drugs?
A4: Only if they avoid infringement on the specific claims or challenge the patent's validity based on prior art.
Q5: Has this patent faced opposition?
A5: No opposition or litigation has been publicly recorded as of the latest data.
References
- European Patent Office. (2014). Patent publication DE13837694.
- European Patent Office. (2013). Patent application prior art and related filings.
- PatentScope. (2023). Patent family analysis for DE13837694.
- United States Patent and Trademark Office. (2022). Related patent documents.
- WIPO. (2022). Patent opposition and litigation records.
